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OBJECTIVES: Despite the progress achieved in the fight against cancer over the past several years, assessing the
needs, goals and preferences of patients with cancer is of the utmost importance for the delivery of health care.
We sought to assess priorities regarding quantity versus quality of life among Brazilian patients, comparing
them with individuals without cancer.
METHODS: Using a questionnaire presenting four hypothetical cancer cases, we interviewed cancer patients,
oncology health-care professionals and laypersons, most of whom had administrative functions in our hospital.
RESULTS: A total of 214 individuals participated: 101 patients, 44 health-care professionals and 69 laypersons.
The mean ages in the three groups were 56, 34 and 31 years old, respectively (p,0.001). The patients had
gastrointestinal (25%), breast (22%), hematologic (10%), lung (8%) or other tumors (36%) and the tumor-
node- metastasis (TNM) stage was I, II, III or IV in 22%, 13%, 34% and 31% of cases, respectively. Treatment
priorities differed significantly among the three groups (p= 0.005), with survival time being a higher priority for
patients than for the other two groups and with opposite trends regarding quality of life. In multivariate
analysis, the age and sex distributions were not associated with the choice to maximize quality of life. In this
limited sample of cancer patients, there were no associations between treatment priorities and disease stages.
CONCLUSIONS: Both survival time and quality of life appeared to be important to cancer patients, oncology
health-care professionals and laypersons, but survival time seemed to have higher priority for people diagnosed
with cancer than for healthy people. Additionally, survival seemed to be more important than quality of life for
all three groups assessed.
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& INTRODUCTION
In recent years, great progress has been achieved in the
fight against cancer (1-3). Improvements in systemic therapy
have considerably brightened the outlook for patients with
the most common types of solid and hematologic malignant
tumors. However, much remains to be done and finding
the right treatment for the right patient has become
the overarching goal of medical oncology (1). Achieving
the goal of personalized cancer care will necessarily entail
the discovery, development and delivery of systemic agents
that can modify the natural history of the disease in
individual patients, according to the specific biological
features of these individuals. However, personalized cancer
care has also been described more broadly, in the context of
advanced cancer, as a need to consider the ‘diverse physical,
psychological, social and spiritual consequences of cancer
for the individual patient’ (4). As a result, assessment of
the needs, goals and preferences of patients with advanced
cancer has been identified as a necessary step toward
tailoring the care delivered to these individuals, who
frequently face the complex consequences of cancer and
its treatment (4).
Despite the achievements of different treatment modal-
ities, a cure has remained elusive for most patients with
advanced solid tumors. Therefore, prolonging survival time
is the key objective in the treatment of these patients (5-10).
However, it is important to assess the priorities of
individual patients in clinical practice. Surveys of patients
with cancer should be able to assess how survival time and
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quality of life, the two chief indicators of treatment benefit
(5), rank in terms of patient priorities and identifying what
patients value more (quantity or quality of life) has been
proposed as an important research topic (11). Apparently,
only a few studies have been performed with the objective
of assessing patient preferences, all of which were con-
ducted in North America, Europe or Japan (11). To our
knowledge, no similar studies have been conducted and
published in Brazil. We thus decided to assess the priorities
of a sample of Brazilian patients with various tumor types at
various stages regarding these two therapeutic objectives,
comparing their preferences with those of health-care
professionals and laypersons. Our primary hypothesis was
that cancer patients would be more likely to prioritize
survival time than quality of life, compared to individuals
without cancer.
& METHODS
Study design and groups of participants
The study protocol for this cross-sectional survey was
approved by the institutional review board of Hospital
Sı´rio-Libaneˆs and all of the participating individuals
provided their written informed consent. We defined
three groups of participants: cancer patients seen in the
Departments of Medical Oncology and Radiation Oncology
at the hospital, health-care professionals working in these
departments and laypersons recruited at the hospital.
Cancer patients and health-care professionals were con-
secutively invited, with no selection criteria other than age
.18 years old, during periods when the data collectors
(GNM, LGDN and GC) were present. The patients’ medical
records were reviewed after their permission was granted
during the consent process. Information on the disease
type and stage was collected from these medical records.
Laypersons were invited at the hospital according to logistic
feasibility and the only selection criterion was the absence of
a personal history of cancer or recent cancer cases in close
family members. The participants received explanations of
the study objectives and methods and they were asked to
complete the study questionnaire (after the consent form
was signed). Each participant was interviewed only once
during the study.
Study questionnaire
The study questionnaire is shown in the Appendix. In
brief, four case vignettes were presented, describing
hypothetical scenarios that were developed by medical
and radiation oncologists and two clinical and research
psychologists. All of the participants were told that the
cases were fictitious and the hypothetical nature of these
scenarios was emphasized in the introduction to the
questionnaire. The first question assessed the participants’
opinions regarding who should be involved in initial
treatment decisions. The second question assessed priorities
regarding different treatment strategies with a preferential
impact on survival time or on quality of life. The third
question presented fictitious patients in four different age
groups (child, adolescent, adult and elderly) in an attempt
to assess preferences for treatment strategies with different
implications in terms of risks and benefits. Finally, the
fourth question was an attempt to quantify the weights
given to survival time and to quality of life. In addition to
multiple-choice options, participants could express their
opinions in textual form, but that information was not
analyzed in the present paper.
Statistical planning and analysis
Our goal was to enroll approximately 250 participants
over a period of 10 months (100 patients, 50 health-care
professionals and 100 laypersons). This sample size was
estimated based on feasibility, rather than on statistical
assumptions. Statistical analyses were performed in a
descriptive fashion for numerical and categorical variables
of interest. Comparisons between groups were conducted
using the chi-square test for categorical variables that were
considered to be of primary importance. Logistic regression
models were used to explore the associations among age,
sex and the types of response to the second question on the
questionnaire. For several of the variables with an explora-
tory nature, no statistical tests were applied. MedCalc
statistical software (version 11.0.0.0, Mariakerke, Belgium)
was used for the analysis and a two-tailed significance level
of 5% was considered significant.
& RESULTS
Flow and characteristics of participants
Between January and September 2010, 214 people were
interviewed: 101 patients, 44 health-care professionals and
69 laypersons, most of whom had administrative functions
in the hospital. The mean (¡ standard deviation) ages in the
three groups were 56 (¡15), 34 (¡9) and 31 (¡7) years
old, respectively (p,0.001). There were also significant
differences in the sex distribution among the groups: the
percentages of women were 53% among patients, 67%
among health-care professionals and 78% among laypersons
(p= 0.004). When pathologic diagnosis was considered in
the group of patients, 25% of individuals had gastrointest-
inal tumors, 22% had breast cancer, 10% had hematologic
malignancies, 8% had lung cancer and 36% had other
tumors. Regarding the tumor-node-metastasis (TNM) dis-
ease stage, 22% of patients had stage I disease, 13% had
stage II, 34% had stage III and 31% had stage IV. Among
the health-care professionals, 35% belonged to the nursing
team, 30% were radiotherapy technicians or physicists,
27.5% were physicians and 7.5% were pharmacists or
biomedicine professionals.
Responsibility for treatment decisions
When asked who should be involved in treatment
decisions for a fictitious patient recently diagnosed with
cancer, the responses of the patient and health-care
professional groups were practically identical and were
only somewhat slightly different from those of the group of
laypersons (Table 1).
Prioritization between survival time and
quality of life
Prioritization between survival time and quality of life
was assessed indirectly, using the second question on the
survey (see the Appendix), for which the participants could
choose among different treatment strategies for a fictitious
patient recently diagnosed with cancer. As shown in Table 2,
there were statistically significant differences the propor-
tions of responses in the three groups, with a graded
increase in prioritizing quality of life across the spectrum,
from patients to health-care professionals to laypersons. An
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exploratory analysis showed no differences in priorities for
the patient group according to TNM stage (I to III versus
IV; data not shown). Moreover, the exploratory analysis
suggested that the age and sex distributions were not
associated with the choice to maximize quality of life in
response to the second question on the questionnaire,
whereas being a layperson was significantly associated
with that choice (see Table 3).
For the third question on the survey, the participants
were asked to select among three treatment strategies for
fictitious patients in four age groups. The responses, shown
in Table 4, showed an overall pattern that varied relatively
little among the participants regarding treatment aggres-
siveness across the four age groups. Survival was prioritized
(i.e., more aggressive treatment) for a 5-year-old child and a
16-year-old adolescent and increasing emphasis was placed
on quality of life (i.e., less aggressive treatment) for a 70-
year-old person (with intermediate results for a 50-year-old
patient).
Finally, the last question on the survey presented six
hypothetical scenarios, each with weights for length of
survival and quality of life, with zero representing the worst
possible situation. Table 5 shows the distributions of
answers in the three groups. However, when the data in
Table 5 were analyzed in only two categories or in one that
considered survival time as the priority (i.e., scenarios A to
C, for which the minimum for survival was 6) and one that
considered quality of life as the priority (i.e., scenarios D to
F), there were statistically significant differences among the
groups (p= 0.007), as shown in Table 6. These results reflect
those shown in Table 2, in the sense that an emphasis on
survival was more common among patients, whereas an
emphasis on quality of life was more frequent among
laypersons.
& DISCUSSION
Ideally, the provision of cancer care should consider the
medical, psychological, social and spiritual consequences of
the disease in each individual patient (4). Therefore,
systematic and objective assessment of patients via surveys
such as that described here can help the clinician and the
oncology community to understand patient priorities and
the extent to which such priorities differ from those of
health-care professionals and laypersons. Brazilian patients
are subjected to specific cultural and social issues that could
result in differences when their psychological responses to
cancer are compared to those of individuals with different
cultural backgrounds. Thus, the current study was a step
toward the important goal of achieving personalized and
culturally appropriate cancer care in this country. Brazilian
investigators have been increasingly influential in the
international oncology community from a scientific point
of view (12) and studies such as the current one should
represent a natural and necessary extension of clinical trials
of novel therapeutic modalities.
Our hypothesis that Brazilian cancer patients would be
more likely to prioritize survival time over quality of life,
compared to individuals without cancer, stemmed from
years of clinical practice with patients and from educational
activities with oncology health-care professionals. Evidently,
this hypothesis emerged based on subjective feelings and
non-systematic observation of the reactions of cancer patients
and health-care professionals to conversations about issues of
survival time and quality of life. Over the years, several of the
authors have developed the impression that health-care
professionals seemed to be more concerned with quality of
life than with the patients themselves, perhaps due to their
professional knowledge of the side effects of treatment and
the prognostic implications of cancer diagnosis. The results of
our survey suggested that there was a graded increase in
concern with the prioritization of quality of life (at the
expense of survival) along the continuum from cancer
patients to oncology health-care professionals to laypersons.
Conversely, an opposite trend appeared to exist regarding
concern about survival duration (at the expense of quality of
life), at least when patients were compared with laypersons.
It should be emphasized, however, that survival was the
chief priority (compared to quality of life) in all three of the
groups assessed.
It is conceivable that the opposite trends in priorities
found in our study were due to the diagnosis of cancer in an
individual, leading to a clearer perception of life’s finiteness
and to a resultant attempt to avoid death at the cost of
quality of life. However, patients’ knowledge regarding
Table 1 - Responses to the question about who should be involved in treatment decisions for a fictitious cancer patient
(the responses did not add up to 100%).
Who should be involved? Patients Health-care professionals Laypersons
The physician 74.7% 75.7% 50.7%
The patient 58.2% 75.7% 44.9%
Relatives 35.4% 48.6% 33.3%
Others members of the health-care team 2.5% 13.5% 14.5%
All 21.5% 21.6% 46.4%
Table 2 - Priorities regarding treatment options for a fictitious cancer patient; the differences among groups were
statistically significant (p= 0.005).
Treatment type Patients Health-care professionals Laypersons
One that prolongs survival, regardless of quality of life. 21.2% 2.3% 11.8%
One that provides a reasonably long life, although not necessarily the
longest, with few side effects and little impact on quality of life.
59.6% 72.7% 54.4%
One that maximizes quality of life, although survival may be shorter. 15.2% 22.7% 33.8%
No treatment should be given. 0% 0% 0%
Do not know or prefer not to comment. 4.0% 2.3% 0%
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their diagnoses was not assessed in the current study and
the extent to which such knowledge contributed to a greater
preference for survival time among patients, compared with
the other two groups, remained uncertain. It is also
conceivable that the preference for quality of life, particu-
larly among laypersons, was due to the emotional re-
moteness of the hypothetical cases presented in the
questionnaire. Finally, it remained possible that age and
sex distributions underlay the different response profiles
across the three groups, despite our exploratory analyses
not suggesting such a possibility.
To our knowledge, studies of this type have been
conducted only in North America, Europe and Japan.
Overall, the available studies have shown that cancer
patients were more frequently willing to face the possibility
of major adverse events in exchange for small objective
benefits, compared to health-care professionals and layper-
sons (11). Slevin et al. (13) and Balmer et al. (14), for
example, found that UK cancer patients were more likely to
accept radical treatment with a minimal chance of benefit
than people without cancer, including physicians and
nurses. Similar results were reported by Bremnes et al. in
Norwegian patients (15). In Japan, patients with lung cancer
were more likely to accept treatment for small benefits
than were patients with other respiratory disorders (16). In
North American women with early-stage breast cancer,
McQuellon et al. (17) assessed patient preferences for
treatment in hypothetical scenarios of metastatic disease;
specifically, the authors attempted to quantify the trade-off
between toxicity and a gain in survival and they found that
a substantial percentage of women would accept the risk of
major toxicity in return for a minimal increase in survival.
Other studies of this type have generally reported similar
trends in terms of patient preferences (11) and our results
were in agreement with those from other countries.
However, it is possible that the patient preferences regarding
treatment depended on patient and disease characteristics.
Hirose et al. (16), for example, found an association between
age and the choice of more aggressive treatment. In the
current study, however, we did not confirm this association
when all of the participants were analyzed in an aggregate
fashion. Regarding disease characteristics, we could not
demonstrate that tumor stage was associated with a pre-
ference for survival time in our patients, but a lack of
understanding regarding patients’ knowledge about their
diagnosis and prognosis might have confounded these
results. Notably, a telephone survey conducted in the US
showed that the most frequent therapeutic goal for patients
with prostate cancer was preservation of quality of life,
followed by extension of life and other objectives, whereas
urologists more frequently focused on survival prolongation
as the goal of therapy (18). Whether such results, which
differed from the overall literature, were due to differences in
disease profile or survey methodology remains unknown.
Generally, most patients with prostate cancer do not face
imminently life-threatening disease, which is a potential
explanation for their preference in the survey by Crawford
et al. (18).
The present study, which should be considered our first
attempt to enhance our understanding of the preferences
and attitudes toward treatment among Brazilian cancer
patients, suffered from limitations. Although the number of
Table 4 - Treatment aggressiveness for fictitious cancer patients in four age groups, according to participant group (see
Appendix for complete definitions of treatment types).
Fictitious
Patient’s age Treatment type Patients
Health-care
professionals Laypersons
5 years old Very toxic, with high chance of cure 84.7% 93.2% 72.5%
Toxic but able to prolong survival 10.2% 4.5% 14.5%
Low toxicity but less effective than others 5.1% 2.3% 13.0%
16 years old Very toxic, with high chance of cure 89.9% 97.7% 78.3%
Toxic but able to prolong survival 7.1% 2.3% 18.8%
Low toxicity but less effective than others 3.0% 0% 2.9%
50 years old Very toxic, with high chance of cure 78.6% 81.0% 64.7%
Toxic but able to prolong survival 16.3% 11.9% 27.9%
Low toxicity but less effective than others 5.1% 7.1% 7.4%
70 years old Very toxic, with high chance of cure 44.3% 18.6% 35.3%
Toxic but able to prolong survival 23.7% 30.2% 17.6%
Low toxicity but less effective than others 32.0% 51.2% 47.1%
Table 3 - Multivariate analysis of factors predicting the choice to maximize quality of life in response to the second
question on the questionnaire
Variable Odds ratio 95% confidence interval p- value
Layperson (patient as reference) 3.34 1.04 - 10.76 0.043
Health-care professional (patient as reference) 1.379 0.37 - 5.22 0.636
Age (as continuous variable) 1.01 0.98 - 1.05 0.519
Sex (female as reference) 0.85 0.37 - 1.95 0.705
Table 5 - Prioritization between survival time and quality
of life (QOL) using weights.
Scenario
Weight for
lifespan
Weight for
QOL Patients
Health-care
professionals Laypersons
A 10 0 11.6% 2.3% 6.0%
B 8 2 13.7% 11.6% 6.0%
C 6 4 28.4% 14.0% 23.9%
D 4 6 26.3% 53.5% 37.3%
E 2 8 14.7% 16.3% 19.4%
F 0 10 5.3% 2.3% 7.5%
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patients investigated in this study was similar to that
enrolled in prior face-to-face surveys (13-15,17), our sample
size was relatively small. Notably, the number of indivi-
duals without cancer, including health-care professionals
and laypersons, was smaller than in previous studies
(13,18). In fact, enrollment for the current study was more
difficult for the latter two groups than for the group of
patients, the vast majority of whom readily agreed to
participate after being invited by the interviewers. A second
limitation, which was already noted, was that we did not
ascertain the patients’ knowledge regarding their diagnoses.
In fact, we made every effort to avoid exposing the patients
to psychological distress resulting from study participation.
As noted previously, the hypothetical nature of the cases
presented was emphasized in the introduction to the
questionnaire. It should be noted, however, that the
patients’ choices might have been related to their knowl-
edge or beliefs about their prognoses (19). A third limitation
was that the current study was conducted at a private
hospital in the city of Sa˜o Paulo and the extent to which the
observed patient preferences were representative of those of
different social classes and regions of the country remains
unknown.
In summary, both survival time and quality of life appeared
to be important to cancer patients, oncology health-care
professionals and laypersons in Brazil. However, the results
of our study suggested that survival time was of higher
priority to people who were diagnosed with cancer, whereas
quality of life appeared to be more important to those for
whom cancer (or, for that matter, the perspective of life’s
finiteness) was a more remote possibility.
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& APPENDIX
STUDY QUESTIONNAIRE (translated from the
original version in Portuguese)
1: A patient has just received a diagnosis of cancer. In
your opinion, who should be involved in the choice of
treatment? Please check as many options as you like.
2: A patient has just received a diagnosis of cancer. The
physician discusses the therapeutic options and the
possible side effects of the treatment with him or her. In
your opinion, which therapeutic modality should be
chosen?
Table 6 - Prioritization between survival time and quality
of life using weights and grouping scenarios (see
Appendix for definitions).
Scenario Patients Health-care professionals Laypersons
A, B or C 53.7% 27.9% 35.8%
D, E or F 46.3% 72.1% 64.2%
% The physician
% The patient
% The relatives
% Others members of the health-care team (nutritionist, psychologist,
physiotherapist, others)
% Everybody
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3: A patient is diagnosed with a highly malignant cancer.
Imagine that there are three therapies available for this
type of cancer, termed X, Y and Z.
Treatment X is quite toxic for the organism and the
patient be hospitalized for approximately one month
until his or her body recovers. Visits will be restricted
due to the patient’s low resistance. There is a high
chance of cure.
Treatment Y can produce nausea, vomiting, fever and
tremors but is less toxic than treatment X. This
treatment should be administered at the hospital once
per week over a year’s time, with no need for
hospitalization. This drug does not cure the disease
but can prolong survival by several months.
Treatment Z consists of an intravenous medication that
must be administered once per month at the hospital.
The patient needs to remain in the hospital for 30
minutes after each application. The most common side
effects are mild, but this treatment is most likely less
effective than treatment Y.
3a): Considering these three treatments, in your opinion,
which one would be the most suitable if the patient were a
five-year-old child? Please justify your answer below.
% Treatment X % Treatment Y % Treatment Z
__________________________________________________________________________________________
__________________________________________________________________________________________
________________________________________
3b): What if the patient were a 16-year-old adolescent?
Please justify your answer below.
% Treatment X % Treatment Y % Treatment Z
__________________________________________________________________________________________
___________________________________________________________________________________________
_______________________________________
3c): What if the patient were a 50-year-old adult? Please
justify your answer below.
% Treatment X % Treatment Y % Treatment Z
_________________________________________________________________________________________
__________________________________________________________________________________________
_________________________________________
3d): What if the patient were a 70-year-old patient? Please
justify your answer below.
% Treatment X % Treatment Y % Treatment Z
________________________________________________________________________________________
_________________________________________________________________________________________
___________________________________________
4: The following table represents six fictitious scenarios. In
each one, there is a value for survival time and another for
quality of life. Both for survival time and for quality of
life, the value zero represents the worst possible situation
(in each case, an immediate risk of death and major
suffering from the disease), whereas a value of 10
represents the best possible situation (an expectation of
a life of many years and no suffering caused by the
disease). The other numbers represent intermediate
situations.
Faced with a diagnosis of cancer, if you could choose only
one of the scenarios above, which would you choose?
Take into account that, for this hypothetical question, we
are considering that you would have to choose either the
length OR the quality of life. In practice, what the doctor
tries to do for the patient is to increase both the lifespan
and quality of life. However, imagine that this would not
be possible and that you actually would have to choose
what you consider to be more important.
% The type that prolongs survival, independent of quality of life
% The type that provides a reasonably long life, although not necessarily
the longest, with minimal side effects and little impact on quality of
life
% The type that provides maximal quality of life, although survival may
be shorter
% No treatment should be given to avoid the risk of side effects or a
negative impact on quality of life
% I do not know or prefer not to comment
SCENARIOS LIFESPAN QUALITY OF LIFE
A 10 0
B 8 2
C 6 4
D 4 6
E 2 8
F 0 10
% Scenario A
% Scenario B
% Scenario C
% Scenario D
% Scenario E
% Scenario F
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